Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | CSNK1D | P48730 | 15/20 | 0.43 |
| ▸ | CSNK1E | P49674 | 15/20 | 0.43 |
| ▸ | KDR | P35968 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14999136 | 0.83 | CSNK1D (0.46) | PIK3CACSNK1DCSNK1EKDR | |
| SCHEMBL172081 | 0.83 | CSNK1D (0.42) | PIK3CACSNK1DCSNK1EKDR | |
| SCHEMBL12664176 | 0.83 | PIK3CA (0.46) | PIK3CACSNK1DCSNK1EKDR | |
| SCHEMBL3713024 | 0.77 | CSNK1D (0.38) | PIK3CACSNK1DCSNK1EKDR | |
| SCHEMBL21033315 | 0.74 | PTGS1 (0.41) | CSNK1DCSNK1E | |
| SCHEMBL26505435 | 0.73 | PIK3CA (0.49) | PIK3CACSNK1DCSNK1EKDR | |
| SCHEMBL13188135 | 0.73 | PIK3CD (0.53) | PIK3CACSNK1DCSNK1E | |
| SCHEMBL30845789 | 0.72 | TGFBR1 (0.43) | CSNK1DCSNK1E | |
| SCHEMBL30845874 | 0.72 | DRD2 (0.40) | CSNK1DCSNK1E | |
| SCHEMBL1318544 | 0.71 | MAP3K5 (0.61) | PIK3CACSNK1DCSNK1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160326180-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-11-10 | — | — | US | disclosed |
| EP-3077393-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | Vertex Pharmaceuticals Incorporated (US) | 2016-10-12 | — | — | EP | disclosed |
| WO-2015084384-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-06-11 | — | — | WO | disclosed |
| US-20150158868-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2015-06-11 | — | — | US | disclosed |
| US-9018208-B2 | Heterocycles as potassium channel modulators | ICAGEN INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-9018208-B2 | Heterocycles as potassium channel modulators | ICAGEN INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-20130143889-A1 | Heterocycles As Potassium Channel Modulators | ICAGEN INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-20130143889-A1 | Heterocycles As Potassium Channel Modulators | ICAGEN INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-8431608-B2 | Heterocycles as potassium channel modulators | ICAGEN INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431608-B2 | Heterocycles as potassium channel modulators | ICAGEN INC. (US) | 2013-04-30 | — | — | US | disclosed |
| EP-2536718-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | Icagen, Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011102964-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011102964-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| US-20100240663-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100240663-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143889-A1 | Heterocycles As Potassium Channel Modulators | KCNK10, KCNK9, KCNJ2 | PIK3CA 1090/4885CSNK1D 2368/4885CSNK1E 2460/4885 |
| US-20150158868-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, MAP3K20, CHEK1 | PIK3CA 84/4885CSNK1D 284/4885CSNK1E 122/4885 |
| US-20160326180-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, MAP3K20, CHEK1 | PIK3CA 84/4885CSNK1D 284/4885CSNK1E 122/4885 |
| US-20100240663-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNK2, KCNK17 | PIK3CA 973/4885CSNK1D 2378/4885CSNK1E 2628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.